Sotrovimab News and Research

RSS

Scientists provide a structural framework for Omicron immune evasion and ACE2 receptor recognition

An interesting preprint research paper describes structural changes resulting from the multiple mutations found in the recent Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is the causative agent behind the coronavirus disease 2019 (COVID-19) pandemic. In addition, the research describes the consequent effects of these changes on Omicron’s infectivity and immune evasion capabilities.

5 Jan 2022

SARS-CoV-2 Omicron variant highly resistant to vaccine-elicited and therapeutic antibodies

Researchers analyzed convalescent sera and sera from immunized individuals to demonstrate the evasion of antibodies by the SARS-CoV-2 Omicron variant.

3 Jan 2022

SARS-CoV-2 Omicron variant neutralized by third BNT162b2 booster shot

A new preprint* research paper under consideration at Nature Portfolio Journal assesses the susceptibility of the Omicron variant to neutralizing antibody response after booster immunization.

28 Dec 2021

Researchers discover antibodies that neutralize omicron and other SARS-CoV-2 variants

An international team of scientists have identified antibodies that neutralize omicron and other SARS-CoV-2 variants. These antibodies target areas of the virus spike protein that remain essentially unchanged as the viruses mutate.

28 Dec 2021

Researchers report loss of antibody potency against SARS-CoV-2 Omicron variant

Researchers find that vaccine-mediated protection against SARS-CoV-2 is significantly reduced against the Omicron variant.

23 Dec 2021

UK government signs two new deals to combat the Omicron variant

Millions more cutting-edge antiviral treatments for COVID-19 have been secured for NHS patients as the UK Government signs two new contracts to help tackle Omicron.

22 Dec 2021

Reduced antibody-mediated neutralization by the SARS-CoV-2 Omicron variant

Researchers discuss the sensitivity of the SARS-CoV-2 Omicron variant towards various monoclonal antibodies.

20 Dec 2021

Impact of SARS-CoV-2 Omicron mutations on the use of therapeutic antibodies in COVID-19 treatment

Researchers investigated the mutations reported in the Omicron variant and its likely impact on the use of therapeutic antibodies in COVID-19 treatment as well as on vaccinated individuals.

17 Dec 2021

Analysis of the alteration of neutralizing titers with Omicron pseudovirus

A new study measured antibody levels from blood samples of vaccinated individuals and individuals who recovered from COVID-19 illness.

17 Dec 2021

New study demonstrates SARS-CoV-2 Omicron antibody escape

A new study examined the neutralization of virus variants using three sets of antibodies: serum from individuals vaccinated or infected with earlier variants of the virus; concentrated human antibodies from plasma donors; and approved monoclonal antibodies.

16 Dec 2021

Monoclonal antibody activity against SARS-CoV-2 Omicron variant

Scientists from Germany have recently pointed out that the third booster dose of mRNA-based COVID-19 vaccine is highly effective in neutralizing the omicron variant of SARS-CoV-2.

15 Dec 2021

Effect of SARS-CoV-2 variant emergence on efficacy of neutralizing antibodies and vaccines

A review article focuses on the efficacy of neutralizing antibodies and vaccines against the SARS-CoV-2 variants.

9 Dec 2021

SARS-CoV-2 Delta variant mutation sites

A new review article dissected the sites of mutation in the RBD of the Delta variant and other variants of concern and variants of alert and interest.

25 Nov 2021

Study shows neutralizing capacity of monoclonal antibodies against SARS-CoV-2 variants of concern

Canadian public health researchers recently published a study in the journal Antiviral Research wherein they described generating a panel of murine hybridomas recognizing SARS-CoV-2 spike protein or nucleoprotein, capable of neutralizing the SARS-CoV-2 variants of concern, proving their therapeutic potential.

17 Nov 2021

Effectiveness of sotrovimab demonstrated in patients with mild to moderate COVID-19

In an attempt to study the safety and effectiveness of sotrovimab in more vulnerable patients suffering from mild to moderate symptoms of COVID-19, a multinational team of researchers conducted the COVID-19 Monoclonal antibody Efficacy Trial-Intent to Care Early (COMET-ICE) trial.

11 Nov 2021